Advances in the Multimodality Management of High-risk Prostate Cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is a heterogeneous disease with marked variability in its natural progression and response to therapeutic interventions. It is the most commonly diagnosed visceral cancer of men living in western countries, yet it is life-threatening in only a minority of cases. Thus, appropriate patient selection for treatment based on tumor as well as patient characteristics is essential to achieve optimal outcomes. The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases.

Original languageEnglish (US)
Pages (from-to)375-394
Number of pages20
JournalSurgical Oncology Clinics of North America
Volume22
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Risk Management
Prostatic Neoplasms
Patient Selection
Neoplasms
Treatment Failure
Early Detection of Cancer
Survival Rate
Therapeutics

Keywords

  • Adjuvant
  • Androgens
  • Chemotherapy
  • Gleason score
  • Prostate cancer
  • Prostatectomy
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Advances in the Multimodality Management of High-risk Prostate Cancer. / Garzotto, Mark; Hung, Arthur.

In: Surgical Oncology Clinics of North America, Vol. 22, No. 2, 04.2013, p. 375-394.

Research output: Contribution to journalArticle

@article{33e32779c70845e1b51d1399fdbe0fa9,
title = "Advances in the Multimodality Management of High-risk Prostate Cancer",
abstract = "Prostate cancer is a heterogeneous disease with marked variability in its natural progression and response to therapeutic interventions. It is the most commonly diagnosed visceral cancer of men living in western countries, yet it is life-threatening in only a minority of cases. Thus, appropriate patient selection for treatment based on tumor as well as patient characteristics is essential to achieve optimal outcomes. The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases.",
keywords = "Adjuvant, Androgens, Chemotherapy, Gleason score, Prostate cancer, Prostatectomy, Radiation",
author = "Mark Garzotto and Arthur Hung",
year = "2013",
month = "4",
doi = "10.1016/j.soc.2012.12.012",
language = "English (US)",
volume = "22",
pages = "375--394",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Advances in the Multimodality Management of High-risk Prostate Cancer

AU - Garzotto, Mark

AU - Hung, Arthur

PY - 2013/4

Y1 - 2013/4

N2 - Prostate cancer is a heterogeneous disease with marked variability in its natural progression and response to therapeutic interventions. It is the most commonly diagnosed visceral cancer of men living in western countries, yet it is life-threatening in only a minority of cases. Thus, appropriate patient selection for treatment based on tumor as well as patient characteristics is essential to achieve optimal outcomes. The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases.

AB - Prostate cancer is a heterogeneous disease with marked variability in its natural progression and response to therapeutic interventions. It is the most commonly diagnosed visceral cancer of men living in western countries, yet it is life-threatening in only a minority of cases. Thus, appropriate patient selection for treatment based on tumor as well as patient characteristics is essential to achieve optimal outcomes. The combination of early cancer detection and technical improvements in local treatment has led to a reduction in disease burden and an increase in cancer survivorship. However, treatment failure remains common among high-risk cases.

KW - Adjuvant

KW - Androgens

KW - Chemotherapy

KW - Gleason score

KW - Prostate cancer

KW - Prostatectomy

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84875541352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875541352&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2012.12.012

DO - 10.1016/j.soc.2012.12.012

M3 - Article

VL - 22

SP - 375

EP - 394

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -